etoposide + cisplatin + carboplatin (Sun Yat-sen University)

chemotherapy-Sun Yat-sen University-small cell lung cancer refers to the platinum-etoposide chemotherapy regimen (consisting of etoposide in combination with either cisplatin or carboplatin) utilized in a Phase II clinical trial (NCT06343103) sponsored by Sun Yat-sen University. This regimen is being evaluated in patients with limited-stage small cell lung cancer (LS-SCLC) as part of a multimodal approach that includes concurrent thoracic radiotherapy, the PD-1 inhibitor toripalimab, and the multi-kinase inhibitor surufatinib. Etoposide functions as a topoisomerase II inhibitor, inducing DNA double-strand breaks by stabilizing the enzyme-DNA complex. Cisplatin and carboplatin are platinum-based alkylating agents that form covalent cross-links with DNA, thereby interfering with DNA replication and transcription, ultimately leading to cell death in rapidly proliferating tumor cells.

Other names

EP regimenEC regimenplatinum-etoposide chemotherapy